Barclays Lowers Organon & Co. (NYSE:OGN) Price Target to $24.00

Organon & Co. (NYSE:OGN) had its price target decreased by stock analysts at Barclays from $26.00 to $24.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 56.91% from the company’s current price.

Several other equities analysts have also recently issued reports on the company. TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Morgan Stanley reduced their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $20.80.

Organon & Co. Trading Down 6.3 %

NYSE:OGN opened at $15.30 on Friday. The firm has a market capitalization of $3.94 billion, a P/E ratio of 3.03, a P/E/G ratio of 0.83 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The company has a fifty day moving average of $15.35 and a 200 day moving average of $17.45. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. On average, research analysts predict that Organon & Co. will post 3.82 earnings per share for the current year.

Institutional Investors Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OGN. Prospera Private Wealth LLC purchased a new position in Organon & Co. during the third quarter valued at $25,000. Horizon Bancorp Inc. IN lifted its position in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after acquiring an additional 1,585 shares during the period. Millstone Evans Group LLC purchased a new position in Organon & Co. during the 4th quarter valued at about $29,000. Larson Financial Group LLC boosted its stake in Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after acquiring an additional 1,734 shares in the last quarter. Finally, Riverview Trust Co grew its holdings in Organon & Co. by 117.7% in the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after purchasing an additional 1,292 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.